Multiple Myeloma

P1, N=42, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting

P1/2, N=161, Completed, Acerta Pharma BV | Active, not recruiting --> Completed | Trial completion date: Apr 2026 --> Oct 2025

In summary, the genomic distinctions now suggest that a proportion of SMMs with progressor phenotype are akin to MM, whereas nonprogressor SMM has monoclonal gammopathy of undetermined significance-like characteristics. The results should influence further investigation in larger studies to inform future diagnostic criteria and trial designs.

These findings provide novel insights into molecular landscape of SBP, highlighting potential for risk stratification and targeted therapy development. The case underscores the importance of comprehensive genomic profiling in rare skull-based tumors to enhance our understanding of their biology and to guide personalized clinical management.

This disruption results in enhanced accumulation of protein aggregates, increased protein polyubiquitination, endoplasmic reticulum stress, and activation of apoptotic pathways. Collectively, our findings support the repurposing of ceritinib in combination with carfilzomib as a translationally relevant and safe strategy to circumvent PI resistance in MM, warranting further clinical investigation in the relapsed/refractory disease setting.

In vivo, the dual CAR compensated for BCMA downregulation when BAFF-R was expressed, preventing the evolution of antigen escape-mutants that drive resistance to CAR T cell therapy. Our study proposes BAFF-R as a complementary target antigen suitable to eliminate malignant plasma cells with less advanced differentiation, lack of BCMA, and occurrence in dismal prognosis patients.

Furthermore, ARRB1 deficiency conferred protection against myeloma-induced bone disease, suggesting a dual role in immune regulation and bone homeostasis. These findings establish ARRB1 as a critical negative regulator of host anti-myeloma immunity and identify it as a potential therapeutic target for enhancing immunotherapy efficacy in MM.

P=N/A, N=27, Not yet recruiting, Assistance Publique - Hôpitaux de Paris

P4, N=15, Recruiting, University Health Network, Toronto | Not yet recruiting --> Recruiting | Trial completion date: Sep 2025 --> Oct 2026 | Trial primary completion date: Apr 2025 --> Jun 2026

By synergizing real-world pharmacovigilance with transcriptomic data, this study delineates novel clinical AE signals and mechanistic insights linking CD38-driven immunometabolic dysregulation to isatuximab toxicity. These findings underscore the imperative for vigilant monitoring and tailored therapeutic strategies to mitigate risks of immune dysfunction, informing both clinical practice and future biomarker-driven interventions.

P=N/A, N=67, Not yet recruiting, Hackensack Meridian Health | Trial completion date: Oct 2027 --> Feb 2028 | Initiation date: Oct 2025 --> Feb 2026 | Trial primary completion date: Oct 2027 --> Feb 2028

P=N/A, N=210, Recruiting, Fundación Española de Hematología y Hemoterapía | Trial primary completion date: Jun 2025 --> Dec 2025